RecruitingPhase 1NCT06942143
An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors
Studying Melanoma of soft tissue
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Guangzhou FineImmune Biotechnology Co., LTD.
- Intervention
- Super1 TCR-T(biological)
- Enrollment
- 15 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2025 – 2027
Study locations (1)
- Sun Yat-sen University Cancer Center, Guangzhou, Gaungdong, China
Collaborators
Sun Yat-Sen University Cancer Center
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06942143 on ClinicalTrials.govOther trials for Melanoma of soft tissue
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06889766NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and SarcomaCentre Hospitalier Universitaire Vaudois
- ACTIVE NOT RECRUITINGNANCT05121545Proton Pencil Beam Scanning GRID for Treatment of Bulky TumorsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- RECRUITINGNCT05231655Ex VIvo DEtermiNed Cancer TherapySheffield Teaching Hospitals NHS Foundation Trust